Valuation: argenx SE

Market Cap 55.53B 49.82B 46.06B 41.71B 77.93B 5,288B 78.87B 551B 219B 2,767B 208B 204B 8,785B P/E 2026 *
30.6x
P/E 2027 * 26.3x
Enterprise Value 51.7B 46.39B 42.89B 38.84B 72.57B 4,924B 73.45B 513B 204B 2,577B 194B 190B 8,180B EV / Sales 2026 *
8.11x
EV / Sales 2027 * 6.38x
Free-Float
99.99%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+1.76%
1 week+1.27%
Current month-5.93%
1 month-5.68%
3 months+3.19%
6 months+19.68%
Current year+11.13%
1 week 771.2
Extreme 771.2
806.2
1 month 682
Extreme 682
862.4
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/25 Sell

Director

4,680 0.0076%
23/11/25 Exercice

Director

4,680 0.0076%
23/11/25 Exercice

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+1.76%+1.27%+11.82%+81.21% 54.55B
+0.65%-3.56%+36.98%+60.50% 63.48B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
+3.72%-6.23%+26.01%-2.99% 23.36B
+1.07%-3.61%-16.22%-3.52% 21.87B
Average +4.21%-0.83%+45.75%+146.19% 40.23B
Weighted average by Cap. +3.12%-0.52%+44.68%+152.50%

Financials

2026 *2027 *
Net sales 6.37B 5.72B 5.29B 4.79B 8.94B 607B 9.05B 63.2B 25.17B 318B 23.91B 23.41B 1,008B 7.77B 6.98B 6.45B 5.84B 10.91B 740B 11.04B 77.11B 30.71B 387B 29.17B 28.56B 1,230B
Net income 1.83B 1.64B 1.51B 1.37B 2.56B 174B 2.59B 18.11B 7.21B 90.99B 6.85B 6.71B 289B 2.11B 1.9B 1.75B 1.59B 2.97B 201B 3B 20.95B 8.35B 105B 7.93B 7.76B 334B
Net Debt -3.82B -3.43B -3.17B -2.87B -5.36B -364B -5.43B -37.91B -15.1B -190B -14.34B -14.04B -605B -5.91B -5.3B -4.9B -4.44B -8.29B -563B -8.39B -58.59B -23.34B -294B -22.17B -21.7B -935B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
28/10/26 €796.60 +1.76% 67,787
27/10/26 €782.80 +0.33% 60,326
26/10/26 €780.20 -0.26% 65,204
23/10/26 €782.20 -0.15% 105,922
22/10/26 €783.40 -0.41% 133,997
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
887.87USD
Average target price
1,121.87USD
Spread / Average Target
+26.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock